Merck Announces Second-Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Merck Announces Second-Quarter 2015 Financial Results
July 28, 2015 7:58 AM EDT
Merck (NYSE: MRK) and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.
Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95 million in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510 million associated with the attainment of certain clinical development, regulatory and commercial... More
July 28, 2015 7:02 AM EDT
Merck (NYSE: MRK) reported Q2 EPS of $0.86, $0.05 better than the analyst estimate of $0.81. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.8 billion.
Merck sees FY2015 EPS of $3.45-$3.55, versus the consensus of $3.45.
Were investing resources... More
